EDITORIAL: Drug Prices Fall 3.1%, the Sharpest Drop Since Kennedy, and Trump Wants All the Credit

March 1963

March 1963.

Kennedy was alive, the Beatles hadn't crossed the Atlantic. America paid for its pills with pocket change.

The last time prescription drug prices fell this fast in the United States.

Since then, the curve has known one direction. It climbed under Democrats, it climbed under Republicans, crisis or no crisis.

Sixty-three years.

An entire American lifetime.

Twelve presidents have come and gone, and every one of them promised to break the pharmaceutical price curve.

Every one of them failed against the most free-spending lobby in Washington.

That lobby has buried more reforms than any other industry. It doesn't even bother hiding it.

Then on August 12, 2026, the Bureau of Labor Statistics publishes its monthly price report. A dry document that markets dissect and households endure.

Page after page of decimals, and buried in them, the price of being sick in America.

Deep in the July columns, one line jumps out. Analysts at the Washington Post and at Axios read it twice.

Prescription drug prices are down 3.1% over twelve months.

The steepest annual drop since March 1963, according to those same analyses of the federal data.

Minus 3.1%.

Three small characters, a minus sign, a three, a one, and sixty-three years of resignation cracking.

Groceries are up, rents are up, overall inflation still runs at 3.4%. One major category is falling.

Analysts call it a statistical anomaly; patients call it oxygen.

The kind that heals.

The number nobody expected

To understand what this number weighs, you have to remember what it replaces.

American drug prices are the highest in the developed world, often two or three times what the same molecule costs in Europe.

Generations of voters built their budgets around that fatality.

The fatality even has its own vocabulary: deductible, copay, coverage gap, an entire lexicon of ransom.

Retirees cut their tablets in half.

Diabetics ration their doses.

A Kaiser Family Foundation survey, cited by Axios, sets the scene. Six in ten Americans still worry about affording their treatments.

Four in ten have already skipped doses or delayed a prescription over money.

Skipping a dose means gambling your health on dice. The house usually wins.

No other wealthy democracy does this to its sick. All of them watch the American exception with a mix of industrial envy and clinical horror.

That is the real country behind the statistic. A country that counts its pills.

Counts them the way the poor count everything: the tablets in the organizer, the days to the next refill, the dollars left on the card.

And in that country, in July, pharmacy prices fell 0.8% in a single month. One month, per the federal report.

Over a year, the medical commodities category is down 2.7%, with prescriptions dragging the whole index lower.

Since the January 2025 inauguration, the White House claims a cumulative decline of 3.9%.

That federal report measures what people actually pay at the counter, month after month, across thousands of sampled pharmacies. Not the speeches, the receipts.

You can argue about the causes, and we will, without indulgence.

You cannot argue about the direction.

For the first time since Kennedy, the medicine cabinet costs less than it did a year ago.

What the administration actually did

Now, the case file.

Because an editorial that applauds without checking is worth no more than an editorial that spits without checking.

Since May 2025, the Trump administration has imposed its most-favored-nation pricing policy on manufacturers. The principle: peg certain American prices to the lowest prices charged in rich countries.

Seventeen manufacturers signed, covering roughly 86% of the American branded-drug market, according to the White House.

The list reads like the index of a stock portfolio, from Pfizer to Eli Lilly.

The lever was blunt and unapologetic, Reuters reports. Three-year exemptions from import tariffs, traded against price cuts.

The bargain was never subtle: cut your American prices, or watch your imports taxed at the border.

Seventeen boardrooms did the math.

Classic Trump.

Feel free to hate the method. Allies have suffered it, markets have cursed it. I have written myself about what it inflicts elsewhere. Except that against the pharmaceutical lobby, that bluntness delivered results. What forty years of commissions never obtained.

The trade stick in the service of a public-health goal.

Pfizer agreed to rebates of up to 85% on certain products, again per Reuters.

Insulins from several manufacturers are now capped at 35 dollars a month. Patient groups had demanded that cap for years.

Eli Lilly cut its flagship treatment Zepbound to 299 dollars a month for direct buyers.

Bristol Myers Squibb offers its blood thinner Eliquis at no cost to Medicaid patients.

Every one of those names sat yesterday among the favorite defendants of campaign season. All parties included, Democrats leading, Republicans close behind.

American public radio counted eighteen major list-price cuts in January. Among them, a fast-acting insulin down 75%. And common heart and diabetes treatments, down 37 to 44%.

These are not campaign promises.

These are posted, verifiable, invoiced prices.

You can walk into a pharmacy and check them yourself, this afternoon, receipt in hand.

The website that sells prescriptions

Then there is the storefront.

In February, the administration launched its own discount drug site, a name so on-brand it makes you wince: TrumpRx.

Set the name aside, a name that turns a public policy into presidential merchandise.

A federal government running a discount storefront for prescriptions: the idea alone would have been unthinkable under any previous administration, of either party.

I find it vulgar, I write that without pleasure, and I say it as a supporter of his record on this file.

The prices, though, do not wince.

Ozempic, listed at 1,028 dollars a month before the deals, sits there around 350 dollars.

The oral version of Wegovy starts at 149 dollars.

Three hundred and fifty dollars is still an indecent sum by world standards, and a deliverance by the standards of an American budget.

Cetrotide, a fertility treatment, drops from 316 dollars to 22.50 dollars.

Ovidrel slides from 251 to 84 dollars, and Gonal-F injections start at 168 dollars.

Fertility treatments, which is to say children made possible, at prices divided by ten. In a country where assisted reproduction bankrupts entire couples.

The White House claims 700 million dollars in sales on the site since launch.

It projects 529 billion in savings over ten years for patients and taxpayers, including 64.3 billion for Medicaid.

Projections, in other words numbers from communications staff, to be treated as such.

The site's name will end up in the archives of political kitsch; the prices end up in household budgets.

I note the kitsch. I keep the prices. So do the households.

But the pharmacy receipt does no communications work.

It reads 350 instead of 1,028, and the person holding it knows exactly what that changes.

That kind of gap doesn't show up in a spreadsheet. It shows up in what's left of the paycheck on the fifteenth of the month.

The share that isn't his

So much for the credit.

Now the shadows, because they exist and they are documented.

Ignoring them would be propaganda, not journalism.

Part of this decline comes from a law Trump has been fighting for years.

Medicare's price negotiations, passed under Biden in the Inflation Reduction Act, took effect in January.

Ten of the best-selling drugs saw their negotiated prices fall by as much as 79%.

Those negotiations, the current administration pockets their fruits while swearing it will rip out the tree. The paradox would be funny if it weren't priced in lives.

Economist Geoffrey Joyce of the University of Southern California says it plainly to the Washington Post. If you're looking for political credit, look at that law first.

The administration answered through its spokesman Kush Desai, who called that reading idiotic and baseless.

An insult is not an argument. It has never refuted an economist.

Both engines are running at once, Biden's and Trump's, and the federal report doesn't sign its lines.

One law negotiates ten blockbuster drugs; one policy claims 86 percent of the branded market. Two levers pulling the same curve, and no instrument that separates their pull.

Cleanly carving up credit for a national curve, nobody knows how to do that, not even the economists who try under oath.

Add waves of generics coming off patent. And the ferocious war among makers of weight-loss drugs. Two market forces that owe nothing to anyone.

An honest president would share the credit.

This one shares nothing, he has never shared anything, and he won't start at seventy-nine. Gratitude is not in his inventory; results are.

So let's do the work in his place: part of the minus 3.1% carries his predecessor's signature.

Writing that down diminishes nothing else.

A columnist who cheats on causes ends up casting doubt on facts. And the facts here are too precious for that.

The hikes in the blind spot

Another caveat, a more disturbing one.

At the very moment the headline cuts were holding the cameras, sixteen signatories raised 872 list prices. Median increase of 4%, in early 2026, from manufacturers supposedly under the spotlight of the deals.

The count comes from the analytics firm 46brooklyn, cited by American public radio.

The firm is no partisan shop: it has documented American drug pricing for years, public figures in hand.

Its founder, Antonio Ciaccia, sees a game of connected vessels. Cut loudly what shows, raise quietly what doesn't.

The federal report captures prices paid at the pharmacy, not the confidential rebates negotiated between manufacturers and insurers.

A stretch of the canvas stays painted black.

What insurers really pay, what middlemen really keep, stays between lawyers and spreadsheets.

Do these caveats cancel the decline?

No.

The overall basket measured by the federal government is falling, hidden hikes included, and that is precisely what makes the number solid.

Put differently, even counting the sleight of hand, the average American pays less for medicine than a year ago.

The magicians failed to make the decline disappear.

But the caveats forbid the fairy tale.

Anyone selling this minus 3.1% as a total and final victory is lying by omission.

It is a partial victory, real and fragile.

All three words count.

This is not a cured system. It is a fever finally breaking.

The victory lap

Naturally, the White House turned the statistic into a parade.

It would have been naive to expect anything else.

The New York Post describes a full victory lap: triumphant statements, video compilations, presidential superlatives calibrated for the evening news.

The greatest drug price drop in history, the administration proclaims in substance. History, rounded to sixty-three years.

The timing is not innocent. Nothing, in a midterm year, ever is.

The midterms are approaching, and the economy remains the president's Achilles heel.

The administration has been hunting for a positive economic story for months, and this is the first one that stands up to the fact-checkers.

The August Reuters-Ipsos poll puts Democrats ahead of Republicans on economic management, 37% to 36%, a first in years.

Presidential approval sits at 35%.

The dashboard blinks red everywhere, except on one line.

In that landscape, a historic drop in drug prices is electoral gold.

Every Florida retiree paying 35 dollars for insulin is a ballot on the move.

The math is obvious, and Democratic strategists know it. They are already searching for a way to contest the number's paternity without appearing to regret the drop.

Should we be scandalized?

I don't see why.

Every government campaigns on its numbers; this one at least has the decency to own a real one.

Democrats did it with factories, Republicans with the stock market. This one does it with the medicine cabinet, and the medicine cabinet speaks to everyone.

The bragging irritates me, the result matters to me, and I know which of the two ends up in pharmacies.

The kitchen table

Back to the kitchen table, where this statistic stops being a statistic and becomes a monthly relief, concrete, dated.

A mother who paid full price for Ozempic gets several hundred dollars back every month. Enough to absorb a grocery bill gone mad.

A couple in fertility treatment watches a 316-dollar invoice melt to 22.50.

Fourteen times less. For a possible child.

A veteran treated by the Department of Veterans Affairs benefits from deals the White House values at more than ten billion.

Executive-branch numbers, once again, to be verified over time, like everything that leaves a communications office in an election year.

What no longer needs verifying is the fear.

The fear of the pharmacy, that American institution.

It doesn't vanish, six in ten still worry, but it is receding for the first time in decades.

A country where four patients in ten skip doses to finish the month is not healed. A curve bending downward heals no one by itself.

It is better treated than before, less ransomed than before, and that progress deserves defending exactly as it is.

The day that ratio truly collapses, we can speak of a cure. Until then, we speak of a reprieve. And in the life of a chronic patient, reprieves count.

Nobody frames a price index on the kitchen wall. People remember the month they stopped choosing between the pharmacy and the electric bill.

Politics, the real kind, is measured there.

Not in press briefings. In the doses no one skips anymore.

Render unto Caesar

Time to conclude, and to conclude honestly.

On this file, Donald Trump delivered.

He took the pharmaceutical lobby head-on, something his predecessors handled with gloves, and he got posted prices moving down.

He used the tariff threat, a tool I criticize elsewhere, to extract concessions persuasion never obtained.

The result is in the federal report, not in his posts.

A report nobody can buy, not even him.

Minus 3.1%.

That number will stay in the textbooks, whatever comes next.

The textbooks will also record the method, tariff blackmail elevated to a public-health instrument. Historians will fight over the percentages between Biden's legacy and Trump's bulldozer.

My support doesn't blind me to the rest. The credit shared with a law he insults. The 872 quiet hikes, the opaque rebates, the vulgarity of the victory lap.

It only obliges me to weigh.

And on the scale, millions of cheaper prescriptions outweigh everything tiresome about the staging.

I would have preferred a president who thanks his predecessors and spares his allies. I have a president who delivers price cuts while insulting everyone. Politics rarely offers the full package.

Render unto Caesar what is Caesar's, even when Caesar gloats.

Especially when Caesar gloats, because that is exactly when his opponents refuse to count the points.

Mine as much as his.

Ten years from now, nobody will remember the website with the ridiculous name or the propaganda clip. What will remain is a line in the statistical series, the first one falling since Kennedy.

And you, the last time you paid for a prescription, did you look at the receipt — and would you have refused the discount because of who signed it?

Sources :

Sources Primaires :

Bureau of Labor Statistics — Consumer Price Index news release, August 12, 2026

White House — President Trump delivers largest prescription drug price drop in over 60 years

White House — Savings from most-favored-nation drug pricing policy

White House — President Trump launches TrumpRx.gov

Sources Secondaires :

Washington Post — Prescription drug prices record sharpest drop in more than 60 years

Axios — Drug prices fall at historic rate

NPR — What TrumpRx and pharma deals mean for drug list prices

Reuters — Global pharma companies that have publicly announced Trump drug pricing deals

New York Post — White House takes victory lap as drug prices dip 3.1%

Reuters — Democrats lead Republicans on economy as Trump approval falls, Reuters-Ipsos poll finds